Neuropathology Core

马萨诸塞州阿尔茨海默病研究中心：神经病理学核心 神经病理学核心服务于马萨诸塞州ADRC（MADRC）和阿尔茨海默病研究 社区通过提供临床评估的诊断验证和向研究者提供组织。 神经病理学评估有助于理解AD/ADRD相关的异质性， 无论是在疾病之间还是在并发的病理过程方面。核心组织的可用性 已被研究人员广泛使用，以加速AD/ADRC的治愈。完成这些 我们有三个目标。 第一组（目标1-3）旨在调动资源，重点是收集、诊断、 收集数据，向家属和相关医生全面报告结果，并进行符合CLIA的尸检 报告通过临床核心，并向数据核心的研究目的-和广泛分布的 支持研究社区的样本。异质性问题直接在这些努力中得到解决。 第二组（目标4-6）旨在制定新战略，采用创新方法 为了确定AD/ADRD中影像学和液体生物标志物的神经病理学基础， AD/ADRD临床试验受试者的神经病理学结果，并从 尸检组织，包括iPSC（将在NCRAD保藏）和分离的细胞类型特异性核。因为这些 三个目标的发展，我们将分享见解，并与其他ADC合作，以验证和广泛的 实施.疾病异质性将在生物标志物基础评估和 信号和临床试验受试者的评估。 最后一组（目标7和8）旨在建设未来，侧重于培训。一是 在AD/ADRD的神经病理学方面培训基础和临床研究人员的组成部分， 组织研究的复杂性和问题。这些工作将与下列机构密切合作进行： 也有努力，与ORE核心合作，在广泛的教育， 尸检和大脑捐赠对加强我们应对AD/ADRD的努力的重要性。 神经病核心与MADRC的所有其他组成部分以及更广泛的科学 社区解决关键问题，以加速治愈AD/ADRD。

Massachusetts Alzheimer’s Disease Research Center: Neuropathology Core The Neuropathology Core serves both the Massachusetts ADRC (MADRC) and the Alzheimer research community by providing diagnostic validation of clinical assessments and providing tissue to investigators. Neuropathologic assessment has contributed to understanding heterogeneity associated with AD/ADRD, both across diseases and in terms of concurrent pathologic processes. The availability of tissue from the Core has been widely used by investigators working to accelerate toward a cure for AD/ADRC. To complete these missions, we have three sets of Aims. The first group (Aims 1-3), which are intended to marshal resources, is focused on the collection, diagnosis, collection of data, full reporting of findings – to families and relevant physicians with a CLIA-compliant autopsy report through the Clinical Core, and to the Data Core for research purposes -- and the wide distribution of samples in support of the research community. Issues of heterogeneity are directly addressed in these efforts. The second group (Aims 4-6), which are intended to develop new strategies, incorporate innovate methods to determine the neuropathologic basis of imaging and fluid biomarkers in AD/ADRD, define the neuropathologic findings in subjects from clinical trials for AD/ADRD and develop new cellular resources from autopsy tissue including iPSCs (to be deposited at NCRAD) and isolated cell-type specific nuclei. As these three aims develop, we will be sharing insights and collaborating with other ADCs for validation and broad implementation. Disease heterogeneity will be addressed in both the assessment of the basis of biomarker signals and in the assessment of clinical trials subjects. The final group (Aims 7 & 8), which are intended to build the future, focus on training. First, there is a component of training basic and clinical researchers in aspects of the neuropathology of AD/ADRD as well as the intricacies and issues around tissue-based research. These efforts will be done in close collaboration with the REC. There are also efforts, done in collaboration with the ORE Core, in broad education about the importance of autopsy and brain donation to enhance our efforts to tackle AD/ADRD. The Neuropath Core interacts with all other components of the MADRC and with the broader scientific community to address critical problems to accelerate towards a cure for AD/ADRD.